{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T18:55:52Z","timestamp":1784400952270,"version":"3.55.0"},"reference-count":46,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Screening for latent tuberculosis infection (LTBI) is mandatory before initiating biologics in patients with chronic inflammatory arthritis (CIA). However, few studies have evaluated the discrepancies between the results of tuberculin skin test (TST) and interferon-\u03b3 release assays (IGRA) in these patients. The purpose of our study was to investigate factors associated with TST and IGRA results in a large cohort of patients with CIA before the introduction of biologics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>A total of 563 consecutive patients with CIA (293 rheumatoid arthritis, 270 spondyloarthritis) and eligible for biologics were prospectively enrolled. Demographic, clinical, and biological data were recorded. Risk factors for LTBI were assessed. All patients underwent a TST, a chest radiograph, and an IGRA test (T-SPOT.TB).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Agreement between the 2 tests was low (\u03ba = 0.16). The bacillus Calmette-Guerin (BCG) status was significantly associated with discordance between the 2 tests (p = 0.004). The TST positivity rate was 34.8%. Factors associated with a negative TST were female sex (p = 0.02) and immunosuppressive treatment (p = 0.003). The only LTBI risk factor associated with TST positivity was an abnormal chest radiograph (p = 0.02). T-SPOT.TB was positive in 21.7% of patients and indeterminate in 15.6%. Previous active TB and chest radiograph abnormalities were associated with IGRA positivity (p = 0.008 and p = 3.9 \u00d7 10<jats:sup>\u22125<\/jats:sup>, respectively). The BCG vaccination was associated with negative IGRA (p = 3 \u00d7 10<jats:sup>\u22124<\/jats:sup>). Indeterminate IGRA results were associated with age, C-reactive protein, and immunosuppressive treatment (p = 0.005, 0.007, and 0.004, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Our data support the combined use of T-SPOT.TB and TST in patients with CIA before biologics introduction. However, despite these good diagnostic values, indeterminate results may complicate the use of IGRA.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.130303","type":"journal-article","created":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T03:03:50Z","timestamp":1380683030000},"page":"1986-1993","source":"Crossref","is-referenced-by-count":25,"title":["Screening for Latent Tuberculosis Infection in Patients with Chronic Inflammatory Arthritis: Discrepancies Between Tuberculin Skin Test and Interferon-\u03b3 Release Assay Results"],"prefix":"10.3899","volume":"40","author":[{"given":"F\u00e9licie","family":"Costantino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"de Carvalho Bittencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Christine","family":"Rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Loeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dintinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"B\u00e9n\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Faure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Chary-Valckenaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2013,10,1]]},"reference":[{"key":"2018112909321472000_40.12.1986.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"2018112909321472000_40.12.1986.2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00028510"},{"key":"2018112909321472000_40.12.1986.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.8.791"},{"key":"2018112909321472000_40.12.1986.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.11137"},{"key":"2018112909321472000_40.12.1986.5","first-page":"247","article-title":"Tuberculose em pacientes reum\u00e1ticos tratados com antagonistas do fator de necrose tumoral alfa: a experi\u00eancia de Portugu\u00eas [Portuguese]. Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience","volume":"31","author":"Fonseca","year":"2006","journal-title":"Acta Reumatol Port"},{"key":"2018112909321472000_40.12.1986.6","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.046797"},{"key":"2018112909321472000_40.12.1986.7","first-page":"683","article-title":"Tuberculosis associated with blocking agents against tumor necrosis factor-alpha\u2014California, 2002\u20132003","volume":"53","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2018112909321472000_40.12.1986.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.21043"},{"key":"2018112909321472000_40.12.1986.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118935"},{"key":"2018112909321472000_40.12.1986.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.24632"},{"key":"2018112909321472000_40.12.1986.11","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.6.968"},{"key":"2018112909321472000_40.12.1986.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029041"},{"key":"2018112909321472000_40.12.1986.13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-9-207"},{"key":"2018112909321472000_40.12.1986.14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-3-199702010-00005"},{"key":"2018112909321472000_40.12.1986.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2006.00941.x"},{"key":"2018112909321472000_40.12.1986.16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.052548299"},{"key":"2018112909321472000_40.12.1986.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(04)01206-X"},{"key":"2018112909321472000_40.12.1986.18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1214673"},{"key":"2018112909321472000_40.12.1986.19","first-page":"620","article-title":"Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy","volume":"137","author":"Beglinger","year":"2007","journal-title":"Swiss Med Wkly"},{"key":"2018112909321472000_40.12.1986.20","first-page":"6","article-title":"Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee","volume":"101","author":"Kavanagh","year":"2008","journal-title":"Ir Med J"},{"key":"2018112909321472000_40.12.1986.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461"},{"key":"2018112909321472000_40.12.1986.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"2018112909321472000_40.12.1986.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133645"},{"key":"2018112909321472000_40.12.1986.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2018112909321472000_40.12.1986.25","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2018112909321472000_40.12.1986.26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641"},{"key":"2018112909321472000_40.12.1986.27","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"2018112909321472000_40.12.1986.28","unstructured":"T-SPOT Oxford Immunotec. Oxford, UK. [Internet. Accessed August 21, 2013.] Available from: www.oxfordimmunotec.com"},{"key":"2018112909321472000_40.12.1986.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200408"},{"key":"2018112909321472000_40.12.1986.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.34382"},{"key":"2018112909321472000_40.12.1986.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101857"},{"key":"2018112909321472000_40.12.1986.32","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05299-11"},{"key":"2018112909321472000_40.12.1986.33","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-008-0519-1"},{"key":"2018112909321472000_40.12.1986.34","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.070789"},{"key":"2018112909321472000_40.12.1986.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2008.12.004"},{"key":"2018112909321472000_40.12.1986.36","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00107608"},{"key":"2018112909321472000_40.12.1986.37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201201-0026OC"},{"key":"2018112909321472000_40.12.1986.38","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-2350"},{"key":"2018112909321472000_40.12.1986.39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007972"},{"key":"2018112909321472000_40.12.1986.40","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00482-10"},{"key":"2018112909321472000_40.12.1986.41","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00122109"},{"key":"2018112909321472000_40.12.1986.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.09.011"},{"key":"2018112909321472000_40.12.1986.43","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.4049\/jimmunol.116.5.1244","article-title":"Effects of C-reactive protein on the lymphoid system. II. Inhibition of mixed lymphocyte reactivity and generation of cytotoxic lymphocytes","volume":"116","author":"Mortensen","year":"1976","journal-title":"J Immunol"},{"key":"2018112909321472000_40.12.1986.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1988.tb02324.x"},{"key":"2018112909321472000_40.12.1986.45","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00117207"},{"key":"2018112909321472000_40.12.1986.46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201979"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.130303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:08:00Z","timestamp":1688515680000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.130303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,12,1]]},"published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.3899\/jrheum.130303"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.130303","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,1]]}}}